Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Carter, Bing Z  [Clear All Filters]
2023
Carter BZ, Mak PYee, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, et al. Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J. 2023;13(1):57.
Carter BZ, Mak PYee Yee, Muftuoglu M, Tao W, Baozhen K, Jiang P, Bedoy AD, Ostermann LB, Nishida Y, Isqandarova S, et al. Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells. Blood. 2023.
2022
Carter BZ, Mak PYee, Tao W, Zhang Q, Ruvolo V, Kuruvilla VM, Wang X, Mak DH, Battula VL, Konopleva M, et al. Maximal activation of apoptosis signaling by co-targeting anti-apoptotic proteins in BH3 mimetic-resistant AML and AML stem cells. Mol Cancer Ther. 2022.
2020
He B, Wang Q, Liu X, Lu Z, Han J, Pan C, Carter BZ, Liu Q, Xu N, Zhou H. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. Biomed Pharmacother. 2020;129:110390.
2019
Beeharry N, Landrette S, Gayle S, Hernandez M, Grotzke JE, Young PR, Beckett P, Zhang X, Carter BZ, Andreeff M, et al. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML. Blood Adv. 2019;3(22):3661-3673.
2015
Carter BZ, Mak PYee, Mak DH, Ruvolo VR, Schober W, McQueen T, Cortes J, Kantarjian HM, Champlin RE, Konopleva M, et al. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget. 2015.
2014
Fidler JM, An J, Carter BZ, Andreeff M. Preclinical antileukemic activity, toxicology, toxicokinetics and formulation development of triptolide derivative MRx102. Cancer Chemother Pharmacol. 2014.